secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000899923-22-000137
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q3 revenue $156.4M, GAAP EPS $(0.43); cuts FY22 guidance; acquires Gateway Genomics for $67.5M
--------------------------------------------------------------------------------

- Revenue $156.4M (-2% YoY); GAAP EPS $(0.43), adjusted EPS $(0.19).
- GeneSight volumes +34% YoY; hereditary cancer volumes +4% YoY; total testing volumes +12% ex-divestitures.
- Acquired Gateway Genomics for $67.5M cash plus up to $32.5M earnout; Gateway expected to be accretive in 2024.
- FY2022 revenue guidance cut to $668-672M (prev. $670-700M); adjusted EPS guided to $(0.35)-$(0.30).
- Quarter-end cash $259.2M, no debt; operating cash flow -$2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/0000899923-22-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/mygn-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer